Screening and identification of gene expression in large cohorts of clinical lung cancer samples unveils the major involvement of EZH2 and SOX2
Preprint
Abstract
Lung adenocarcinoma (LUAD), the primary subtype of Non-Small Cell Lung Cancer (NSCLC), accounts for 80% to 85% of cases. Due to suboptimal screening method, LUAD is often detected in late stage, leading to aggressive progression and poor outcomes. Therefore, early disease prognosis for the LUAD is high priority. In order to identify early detection biomarkers, we conducted a meta-analysis of mRNA expression TCGA and GTEx datasets from LUAD patients. A total of 795 differentially expressed genes (DEGs) were identified by exploring the Network-Analyst tool and utilizing combined effect size methods. DEGs refer to genes whose expression levels are significantly different (either higher or lower) compared to their normal baseline expression levels. KEGG pathway enrichment analysis highlighted the TNF signaling pathway as being prominently associated with these DEGs. Subsequently, using the MCODE and CytoHubba plugins in Cytoscape software, we filtered out the top 10 genes. Among these, SOX2 was the only gene exhibiting higher expression, while the others were downregulated. Consequently, our subsequent research focused on SOX2. Further transcription factor-gene network analysis revealed that enhancer of zeste homolog 2 (EZH2) is a significant partner of SOX2, potentially playing a crucial role in euchromatin-heterochromatin dynamics. Structure of SOX2 protein suggest that it is a non-druggable transcription factor, literature survey suggests the same; hence, we drove our focus to investigate on potential drug(s) targeting EZH2. Molecular docking analyses predicted most probable inhibitors of EZH2. We employed several predictive analysis tools and identified GSK343, as a promising inhibitor of EZH2.Keywords
This publication has 63 references indexed in Scilit:
- Dissecting SOX2 expression and function reveals an association with multiple signaling pathways during embryonic development and in cancer progressionBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024
- Mechanisms of hedgehog, calcium and retinoic acid signalling pathway inhibitors: Plausible modes of action along the MLL–EZH2-p53 axis in cellular growth controlArchives of Biochemistry and Biophysics, 2023
- Epigenetic regulation of pluripotency inducer genes NANOG and SOX2 in human prostate cancer2023
- Applications and developments of gene therapy drug delivery systems for genetic diseasesAsian Journal of Pharmaceutical Sciences, 2021
- Epigenetic silencing of genes enhanced by collective role of reactive oxygen species and MAPK signaling downstream ERK/Snail axis: Ectopic application of hydrogen peroxide repress CDH1 gene by enhanced DNA methyltransferase activity in human breast cancerBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2019
- The Gene Expression Omnibus Database2016
- EZH2-Induced H3K27me3 is Associated with Epigenetic Repression of the ARHI Tumor-Suppressor Gene in Ovarian CancerCell Biochemistry and Biophysics, 2014
- Downregulation of a putative tumor suppressor BMP4 by SOX2 promotes growth of lung squamous cell carcinomaInternational Journal of Cancer, 2014
- Cytoscape: Software for Visualization and Analysis of Biological Networks2010
- Clinical Uses of Microarrays in Cancer Research2008